Thermo Fisher opens Swiss biologics manufacturing plant
Lengnau will become the newest site in Thermo Fisher Scientific’s biologics manufacturing network. The site is to be completed in 2022 and its staff of 200 will join the company.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 241 entries already.
Entries by Uta Mommert
UK clears the way for gene-edited crops
Post-Brexit, UK ditches the strict EU regulation for genetic engineering: in future, gene-edited crops will be assessed just like any other new variety, the government said.
AstraZeneca invests in saRNA platform
AstraZeneca has teamed up with RNA vaccine and therapeutic developer VaxEquity, investing US$195m in milestone payments alone.
Boehringer Ingelheim: Takeover in immunooncology
Boehringer Ingelheim has acquired Texan biotech Abexxa Biologics Inc., further expanding its cancer immunotherapy pipeline.
Bayer: Peptide deal with Gubra
Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.
Foundation launches Harvard research hub
The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.
Meatable teams up with Royal DSM
Royal DSM is backing Meatable, the cultivated meat start-up, in order to develop growth media for cultivated meat.
US$21m for microbiome therapies
EnteroBiotix closes an oversubscribed Series A financing with US$21.5m. The biopharma company will use the proceeds to advance its microbiome drug pipeline.
Owlstone: US$59m for breath biopsy development
Owlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the company’s breath biopsy tests.
EU ends litigation with AstraZeneca
The EU Commission and AstraZeneca have settled their ongoing legal dispute over the supply of COVID-19 vaccine doses. They agreed to a new delivery schedule.